He told Outsourcing-pharma that: “There has been a clear trend over the last few years for companies to look for the ‘one-stop solution ’approach to outsourcing services. In keeping with this companies also want a single entry point to all CTS services.
“With a single interface we offer our clients an integrated full service approach to development of drug dosage forms,” Marett continued, adding that customers report that NextPharma’s integrated approach minimises costs and timings.
One of the key advantages, explained Marett, is that: “clients do not have to negotiate separate commercial and quality contracts, or audit numerous different outsourcing suppliers, all of which represents a significant drain on resources.”
The new clinical trial capabilities include randomization double-blinding, generation of emergency letters, packaging, kitting, labelling, cold-chain storage, distribution, return accountability and destruction.
The San Diego plant also provides pharma industry customers with lyophilization services for vial sizes 2ml to 100ml, for batches ranging in size from 25 to 10,000 vials per batch.
In a press release issued last week, CEO Bill Wedlake, said that the firm is excited about the new offering, explaining that “our clinical trial services personnel have proven expertise in supporting global clinical trials for pharmaceutical, biotechnology, academic and research organisations.”
“This new service will leverage our growing presence in pharmaceutical development and contract manufacturing in the US.”
The US services mirror those already provided by NextPharma’s facility in Gottingen, Germany.